Evidence map›Paper›PMID 42805423›Full record

ArticleBrain, behavior, and immunity2026

Epigenetic C-reactive protein and corticolimbic gray matter volume in youth at clinical high risk for psychosis.

Benson S Ku, Ying Xu, David R Goldsmith, Chelsea Sawyers, Jean Addington, Carrie E Bearden, Kristin S Cadenhead, Tyrone D Cannon, Ricardo E Carrion, Matcheri S Keshavan and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain, behavior, and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Benson S KuDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: bsku@emory.edu.
Ying XuDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.
David R GoldsmithDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.
Chelsea SawyersVirginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, USA.
Jean AddingtonDepartment of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
Carrie E BeardenDepartments of Psychiatry and Biobehavioral Sciences and Psychology, Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, USA.
Kristin S CadenheadDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Tyrone D CannonDepartment of Psychiatry, Yale University, New Haven, CT, USA; Department of Psychology, Yale University, New Haven, CT, USA.
Ricardo E CarrionDivision of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA; Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA; Department of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Matcheri S KeshavanDepartment of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center, Boston, MA, USA.
Daniel H MathalonDepartment of Psychiatry & Behavioral Sciences, University of California, San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA.
William S StoneDepartment of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center, Boston, MA, USA.
Scott W WoodsDepartment of Psychiatry, Yale University, New Haven, CT, USA.
Elaine F WalkerDepartment of Psychology, Emory University, Atlanta, GA, USA.
Diana O PerkinsDepartment of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Anne K BozackDepartment of Population Health, NYU Grossman School of Medicine, New York University, New York, NY, USA.

Funding

STRESS AND EMOTIONAL REACTIVITYP50MH066286 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NUECHTERLEIN, KEITH H · 2003 to 2014
$18.6M
1/9 Predictors and Mechanisms of Conversion to PsychosisU01MH081902 · NIMH · YALE UNIVERSITY · PI CANNON, TYRONE D · 2008 to 2018
$12.4M
5/9 Predictors and Mechanisms of Conversion to PsychosisU01MH082004 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PERKINS, DIANA O. · 2008 to 2018
$7.5M
Administrative Supplement Harmonization of At Risk Multisite Observational Networks for Youth(HARMONY)U01MH081928 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI STONE, WILLIAM SETH · 2008 to 2018
$7.1M
4/9-Predictors and Mechanisms of Conversion to PsychosisU01MH081857 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI CORNBLATT, BARBARA A. · 2008 to 2018
$6.2M
8/9 Predictors and Mechanisms of Conversion to PsychosisU01MH082022 · NIMH · YALE UNIVERSITY · PI WOODS, SCOTT W · 2008 to 2018
$6.0M
2/9 - Predictors and Mechanisms of Conversion to PsychosisU01MH081988 · NIMH · EMORY UNIVERSITY · PI WALKER, ELAINE FRAN · 2008 to 2018
$5.4M
6/9-Predictors and Mechanisms of Conversion to PsychosisU01MH081944 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CADENHEAD, KRISTIN S. · 2008 to 2018
$4.9M
"7/9" Predictors and Mechanisms of Conversion to PsychosisU01MH081984 · NIMH · UNIVERSITY OF CALGARY · PI ADDINGTON, JEAN M · 2008 to 2018
$4.2M
Functional Brain Abnormalities in the Schizophrenia ProdromeR01MH076989 · NIMH · YALE UNIVERSITY · PI MATHALON, DANIEL H · 2007 to 2014
$2.3M
Impact of Neighborhood Characteristics on Conversion to Psychosis among Youth at Clinical High Risk for PsychosisK23MH129684 · NIMH · EMORY UNIVERSITY · PI Benson Ku · 2022 to 2026
$970k
NIMH NIH HHS K23 MH129684NIMH NIH HHS P50 MH066286NIMH NIH HHS R01 MH076989NIMH NIH HHS U01 MH081857NIMH NIH HHS U01 MH081902NIMH NIH HHS U01 MH081928NIMH NIH HHS U01 MH081944NIMH NIH HHS U01 MH081984NIMH NIH HHS U01 MH081988NIMH NIH HHS U01 MH082004NIMH NIH HHS U01 MH082022
6 · The paper itself

Abstract

aimsInflammation and structural brain alterations are implicated in psychosis risk, yet it remains unknown whether epigenetic C-reactive protein (CRP), a DNA methylation-based estimator of cumulative inflammatory burden, is associated with brain structure in youth at clinical high risk for psychosis (CHR-P).

methodsWe examined associations between epigenetic and plasma CRP, regional gray matter volume (GMV), and positive symptom severity in 165 participants (108 CHR-P, 57 healthy comparison [HC] participants) from the North American Prodrome Longitudinal Study Phase 2. Epigenetic CRP was derived from the Illumina 450K array; plasma CRP was quantified in a subset of 81 participants via multiplex immunoassay. GMVs of the medial prefrontal cortex, anterior cingulate cortex (ACC), and hippocampus were extracted from 3-Tesla MRI scans; positive symptoms were assessed with the Scale of Prodromal Symptoms.

resultsEpigenetic and plasma CRP were weakly correlated (r = 0.19). Higher epigenetic CRP was associated with lower GMV in several corticolimbic regions, including the left caudal ACC (cACC; β = - 0.08, p = 0.011), and lower cACC volume was associated with greater positive symptom severity (β = - 0.26, p = 0.001). Plasma CRP showed no significant associations in the primary combined-sample model.

conclusionsTo our knowledge, this study is the first to show that epigenetic CRP is associated with corticolimbic structural differences in CHR-P and HC youth. Epigenetic CRP may capture inflammation-related neurostructural variation relevant to psychosis risk.

Identifiers

PMID42805423
PMCPMC13673434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.